RxDoctor Payments Data

Larry Berman, MD

Internal Medicine · Charlotte, NCNPI 1508869835

Payments from drug & device makers

$300,608in general payments, 2019–2025

Across 731 payments — averaging $411.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$95K
  • AbbVie$47K
  • Hikma Pharmaceuticals USA$44K
  • Chiesi USA, Inc.$42K
  • GRT US Holding, Inc.$20K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$19K
  • plus $33K from 44 others

What the payments were for

  • Consulting fees$4504%
  • Speaking & faculty fees$200%
  • Food & beverage$10,11193%
  • Education$2963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$300,608 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$142,547
Medicare patients
389
Services billed
1,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$86,631
FarxigaDapagliflozin Propanediol47$39,939
XareltoRivaroxaban22$26,458
OzempicSemaglutide16$21,240
JanuviaSitagliptin Phosphate21$17,362
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$11,934
AbrysvoRsv Vacc, Pref A And Pref B/Pf33$10,543
ShingrixVaricella-Zoster Ge/As01b/Pf14$3,111
Atorvastatin Calcium399$2,844
SynthroidLevothyroxine Sodium22$2,496
Rosuvastatin Calcium143$1,709
Gabapentin112$1,635
Tamsulosin Hcl142$1,454
Amlodipine Besylate231$1,448
Losartan Potassium158$1,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$534$97,174141 claims
AstraZenecaFarxiga$10,004$39,93947 claims
Johnson & JohnsonXarelto$98$26,45822 claims
Novo NordiskOzempic$1,365$21,24016 claims
MerckJanuvia$369$17,36221 claims
GSKShingrix$327$3,11114 claims
AbbVieSynthroid$46,912$2,49622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →